Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Iovance Biotherapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 286
- +26 vs. Q4 2025
- Shares held
- 269.1M
- +34.8M (+14.8%) vs. Q4 2025
- Total value
- $943.8M
- +$304.4M (+47.6%) vs. Q4 2025
- New holders
- 64
- 122 more added
- Sold out
- 38
- 58 more reduced
3 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOVA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 293 | $1.19B |
| Q1 2026 | 286 | $943.8M |
| Q4 2025 | 263 | $713.7M |
| Q3 2025 | 253 | $462.3M |
| Q2 2025 | 255 | $379.3M |
| Q1 2025 | 303 | $798.9M |
| Q4 2024 | 302 | $1.79B |
| Q3 2024 | 286 | $2.21B |
| Q2 2024 | 295 | $1.86B |
| Q1 2024 | 273 | $3.22B |
| Q4 2023 | 236 | $1.69B |
| Q3 2023 | 228 | $970.0M |
| Q2 2023 | 219 | $1.44B |
| Q1 2023 | 230 | $1.25B |
| Q4 2022 | 218 | $1.11B |
| Q3 2022 | 242 | $1.48B |
| Q2 2022 | 238 | $1.75B |
| Q1 2022 | 248 | $2.60B |
| Q4 2021 | 246 | $2.96B |
| Q3 2021 | 244 | $3.88B |
| Q2 2021 | 234 | $4.22B |
| Q1 2021 | 252 | $4.98B |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Iovance Biotherapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Shay Capital LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Adams Wealth Management | 0 | $0 | 0.00% | −19,227−100.0% | Sold out |
| CacheTech Inc. | 0 | $0 | 0.00% | −19,227−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −19,209−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −19,089−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −16,872−100.0% | Sold out |
| Mackenzie Financial Corp | 0 | $0 | 0.00% | −16,360−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −15,300−100.0% | Sold out |
| HBK Sorce Advisory LLC | 0 | $0 | 0.00% | −15,027−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −12,788−100.0% | Sold out |
| M&T Bank Corp | 0 | $0 | 0.00% | −11,464−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −9,661−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −2,819−100.0% | Sold out |
| Smartleaf Asset Management LLC | 0 | $0 | 0.00% | −2,090−100.0% | Sold out |
| Torren Management, LLC | 0 | $0 | 0.00% | −1,348−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −1,006−100.0% | Sold out |
| Bell Investment Advisors, Inc | 0 | $0 | 0.00% | −1,070−100.0% | Sold out |
| Hurley Capital, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Navalign, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −315−100.0% | Sold out |
| Shelton Wealth Management, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Optima Capital LLC | 0 | $0 | 0.00% | −242−100.0% | Sold out |
| Pier 88 Investment Partners LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |